Moreover, the 36-month beta value for SLDB is 2.30. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLDB is 64.40M and currently, short sellers hold a 12.52% of that float. On April 28, 2025, SLDB’s average trading volume was 2.61M shares.
SLDB) stock’s latest price update
The stock price of Solid Biosciences Inc (NASDAQ: SLDB) has dropped by -10.08 compared to previous close of 3.67. Despite this, the company has seen a gain of 29.41% in its stock price over the last five trading days. seekingalpha.com reported 2025-04-08 that Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly impacted Solid’s stock price, creating a potential recovery opportunity if Sarepta clarifies the isolated nature of the patient’s death. Solid’s pipeline includes SGT-003 for DMD, SGT-212 for Friedreich’s ataxia, and SGT-501 for CPVT, with promising early data and no serious adverse effects.
SLDB’s Market Performance
Solid Biosciences Inc (SLDB) has experienced a 29.41% rise in stock performance for the past week, with a -22.54% drop in the past month, and a 2.80% rise in the past quarter. The volatility ratio for the week is 13.51%, and the volatility levels for the past 30 days are at 11.43% for SLDB. The simple moving average for the past 20 days is 4.99% for SLDB’s stock, with a -42.35% simple moving average for the past 200 days.
Analysts’ Opinion of SLDB
Many brokerage firms have already submitted their reports for SLDB stocks, with Truist repeating the rating for SLDB by listing it as a “Buy.” The predicted price for SLDB in the upcoming period, according to Truist is $16 based on the research report published on January 08, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see SLDB reach a price target of $16. The rating they have provided for SLDB stocks is “Outperform” according to the report published on December 13th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to SLDB, setting the target price at $15 in the report published on December 10th of the previous year.
SLDB Trading at -24.16% from the 50-Day Moving Average
After a stumble in the market that brought SLDB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.97% of loss for the given period.
Volatility was left at 11.43%, however, over the last 30 days, the volatility rate increased by 13.51%, as shares sank -24.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.52% lower at present.
During the last 5 trading sessions, SLDB rose by +29.41%, which changed the moving average for the period of 200-days by -50.45% in comparison to the 20-day moving average, which settled at $3.14. In addition, Solid Biosciences Inc saw -17.50% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLDB starting from Kahn Clare, who purchase 1,860 shares at the price of $5.34 back on Mar 11 ’25. After this action, Kahn Clare now owns 2,960 shares of Solid Biosciences Inc, valued at $9,924 using the latest closing price.
Bain Capital Life Sciences Inv, the 10% Owner of Solid Biosciences Inc, purchase 1,000,000 shares at $4.03 during a trade that took place back on Feb 19 ’25, which means that Bain Capital Life Sciences Inv is holding 5,034,582 shares at $4,030,000 based on the most recent closing price.
Stock Fundamentals for SLDB
The total capital return value is set at -0.82. Equity return is now at value -94.57, with -70.53 for asset returns.
Based on Solid Biosciences Inc (SLDB), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -4.14. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -381.55.
Currently, EBITDA for the company is -129.73 million with net debt to EBITDA at 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.20.
Conclusion
To wrap up, the performance of Solid Biosciences Inc (SLDB) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
